Delivery Order SPE2DB22D2206-SPE2DB24FJV63

Award Date 8/16/24
Potential Completion Date 9/9/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $7,436.04 firm fixed price delivery order is for 1,400 mg-23,400 11.7 ml units of the medication Rituxan Hycela. The contract has a completion date of June 13, 2025. AmerisourceBergen Drug Corp holds a large Indefinite Delivery Contract (IDC) valued at $999,999,999.00 with DLA Troop Support Medical, which provides a comprehensive global...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract, valued at $3,718.02, is for the delivery of Rituxan Hycela 1,400 mg-23,400 11.7 ml. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of May 21, 2025. The contract is not set aside and is open to competition. Amerisourcebergen Drug Corp is the prime contractor and holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 1,400 mg-23,400 11.7 ml vials of the drug Rituxan Hycela, with a ceiling value of $74,092.00 and a completion date of June 7, 2023. The contract was awarded on May 16, 2023 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,308.12, is for the delivery of RITUXAN HYCELA 1,400 MG-23,400 11.7ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance through February 4, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite...
This federal contract award (SPE2DB20D3103|SPE2DB22FM4X7) was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 1,400 mg-23,400 11.7 ml units of the drug Rituxan Hycela. The contract has a ceiling value of $11,738.44 and was awarded on a firm fixed-price basis, with a completion date of February 23, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
This federal contract award, valued at $8,083.97, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,892.20 firm fixed-price delivery order is for the supply of 4,566,692,708 units of the medication RUXIENCE 500 MG/50 ML VIAL 50ML. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order award valued at $3,198.40 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract covers critical medical commodities including specialty...
This is a delivery order award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical for $115,033.56. The award is part of a larger Indefinite Delivery Contract (IDC) with the DLA valued at $999,999,999 that covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract includes specialty medications, brand-name and generic drugs, vaccines,...
This is a delivery order award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $14,783.50 firm-fixed-price contract covers the provision of various pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) valued...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FJV63
    Delivery Order

This is a delivery order award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $14,627.04, is for the delivery of 4,565,483,195 units of the biopharmaceutical product Rituxan Hycela 1,400 mg-23,400 11.7 ml. This contract supports the federal government's medical supply needs, providing critical care medications to military treatment facilities and other federal healthcare programs. The award does not have a set-aside designation and has a period of performance through September 9, 2024.

Generated 11/15/24, 9:18 AM